Lowering Insulin Costs: Sanofi Seeks HHS Support For Expanding Assistance To Medicare Patients
Executive Summary
HHS endorsement of company-sponsored discount programs for cash-paying customers with Medicare would be preferable to lowering list pricing.
You may also be interested in...
Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.
Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.
Lilly Likes Concept Of Low-Cost Brand Alternatives As ‘Glide Path’ To No Rebates
Approach could be useful for quickly lowering the cost of insulins, Express Scripts’ Miller points out.